Pharmacy and Therapeutics Committee Updates

(From the September 2018 Issue of MedStat)

The following actions were taken at the 8/2/18 Pharmacy & Therapeutics Committee meeting:

  • Updated ENT Stock Lists were APPROVED 
  • Admelog (insulin lispro) was NOT ADDED to formulary due to cost and dose increment limitations.  Humalog (insulin lispro) remains the formulary product.
  • Bivalirudin (Angiomax) was ADDED to formulary with limited prescribing privileges and patient unit restrictions
  • Lumason (sulfa hexafluoride microspheres) 6 month review was APPROVED to remain on formulary
  • Topical Capsaicin  6 month review was APPROVED to remain on formulary
  • SMOFlipid 6 month review was APPROVED to remain on formulary